Company intelligence / Profile preview

Biochallenge

Seoul, South Korea

Ownership: Private
Employees: ~25
Development stage: Other

Overview

Biochallenge is a South Korean biotechnology company focused on developing innovative treatments for hair loss and regenerative medicine. The company's core technology centers on the Wnt/beta-catenin signaling pathway, specifically targeting the CXXC5 protein which acts as a negative regulator of this pathway. By inhibiting the interaction between CXXC5 and Dishevelled (DVL), Biochallenge aims to promote hair follicle regeneration and bone formation. Their lead programs include small molecule and peptide-based therapies currently in preclinical development. The company was founded by Professor Kang-Yell Choi, a leading expert in Wnt signaling research from Yonsei University.

Therapeutic areas: EndocrinologyDermatology
Modalities: Small moleculePeptides
Industry: Biotech

Beyond the preview

Go deeper on Biochallenge.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Biochallenge.

Explore the full profile